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Introduction
Bronchovascular reconstructive procedures employed 
in order to avoid pneumonectomy (PN) in functionally 
unsuitable patients have provided, over time, excellent 
results, similar or even better than those obtained by 
PN. In recent years, new successful techniques have 
been developed that pertain in particular the prevention 
of major complications and the reconstruction of the 
pulmonary artery (PA). Encouraging data from increasing 
number of published experiences support the choice of 
parenchymal sparing procedures for lung cancer also in 
patients with good functional reserve. This is even more 
true if considering trials published in the last 10 years, 
thus indicating that improved outcome can be achieved 
with increased experience in reconstructive techniques and 
perioperative management (1,2). This article discusses the 
main technical aspects and results of literature.
Indications and preoperative study
The indication for a sleeve resection in patients with lung 
cancer is a tumor located at the origin of a lobar bronchus, 
at the origin of the lobar branches of the PA, or both, but 
not infiltrating the remaining lobes as far as to require PN 
(Figure 1). In addition, a sleeve resection may be indicated 
when N1 nodes infiltrate the bronchus and/or the PA from 
the outside. This condition can frequently be found in 
patients with left upper lobe tumors needing a combined 
reconstruction of the bronchus and the PA.
It is not always easy to establish the correct indication 
for a reconstructive procedure before surgery. Computed 
tomography (CT) with contrast medium is the most used 
diagnostic tool. Bronchial infiltration can be confirmed 
more clearly by a preoperative bronchoscopy, and only 
in a few cases intraoperative exploration shows a tumor 
infiltration limited to the external surface of the bronchial 
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wall not visible at the endoscopic evaluation.
In contrast,  the correct indication for a sleeve 
resection of the PA may be more difficult to define by the 
preoperative study. Angiography and magnetic resonance 
imaging of the blood vessels can provide useful information 
to assess the pattern of vascular infiltration, but the decision 
is usually made during surgery. PA infiltration degree and 
extension are not always clearly shown at preoperative 
imaging. Sometimes discrepancies between radiological 
evidence and intraoperative findings may be responsible 
for wrong indications, because the preoperative study may 
overestimate or underestimate the vascular involvement (3).
Establishing the correct indication generally becomes 
more complex and controversial after induction therapy. 
At preoperative CT re-evaluation it is usually difficult to 
distinguish diffuse desmoplastic reaction and fibrosis related 
to chemotherapy and radiotherapy from residual tumor.
The final decision to perform a sleeve lobectomy (SL) 
as an alternative to standard lobectomy or PN is therefore 
generally taken by the surgeon based on intraoperative 
findings. Because doubts about the presence of viable tumor 
in the context of fibrotic scarring tissue may persist, extensive 
use of intraoperative frozen-section analysis is mandatory in 
order to choose the most appropriate oncologic operation.
Fiberoptic bronchoscopy is the cornerstone of bronchial 
evaluation. In the setting of a multimodality treatment 
including surgery it is important that this examination 
is performed by one of the operating surgeons, ideally 
with the possibility of comparing the bronchus status 
after induction therapy with that observed before the 
induction therapy. Careful evaluation of the bronchial 
motion can provide useful information on the state of 
tissues outside the bronchus: stiffness of the bronchial 
wall may indicate peribronchial tumor infiltration. 
Endobronchial ultrasonography has improved the accuracy 
of bronchoscopic evaluation in recent years.
It is still a matter of debate whether, in cases of viable 
tumor in the main bronchus at presentation that is no 
longer visible after neoadjuvant therapy, a parenchyma-
sparing operation should be considered instead of a PN.
The primary oncologic goal in every case is the complete 
resection of the tumor with free resection margins. Based on 
this principle the authors’ approach is to tailor the extent of 
resection according to the results of frozen-section analysis.
This policy is also justified by the evidence from 
literature data that PN, especially right PN, is itself a 
disease, with severe impairment of lung function and quality 
of life after surgery (4,5). This intervention should therefore 
be avoided whenever possible.
Another controversial issue is whether the presence 
of N1 disease should dictate the indication for a PN, 
because of the higher risk of tumor cell diffusion through 
the peribronchial lymphatic vessels in the adjacent 
macroscopically uninvolved lung districts. There is evidence 
in the literature, for patients with positive hilar nodes, that 
SL is related to lower morbidity and mortality and better 
long-term results than PN (6-8). These data support the 
choice of a parenchyma-sparing operation in this setting.
Technical issues
Dissection
Anatomic and technical considerations in this article mainly 
refer to upper lobe disease because most surgical procedures 
are performed for tumors originating in this location, 
whereas reconstructions for tumors of the lower and middle 
lobe are rarer.
A crucial step of the operation consists in achieving full 
control of the proximal portion of the PA. The PA can be 
isolated on both sides extrapericardially if the infiltration is 
found only distally near the interlobar fissure. However, in 
many patients the artery may be involved close to its origin, 
and therefore the pericardium has to be opened to apply the 
proximal arterial clamping. The pericardium is generally 
incised longitudinally behind the phrenic nerve to confirm 
that the origin of the PA is free from tumor and to allow its 
preparation. On the right side, extrapericardial preparation 
Figure 1 Indication for sleeve lobectomy, CT scan images. The tumor 
infiltrates both the bronchus and the pulmonary artery on the left side. 
CT, computed tomography.
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can be facilitated with the anterior and medial retraction of 
the superior vena cava (SVC). When proximal infiltration 
of the artery is close to the pericardial reflection, the PA can 
be isolated and clamped transpericardially between the SVC 
and the ascending aorta. The vessel is then encircled by an 
umbilical tape. In general, the isolation of the pulmonary 
veins is less problematic because these vessels are located far 
from most tumors that are amenable to a sleeve resection. 
Involvement of the superior pulmonary vein can be found 
on the left side of tumors infiltrating the anterior aspect of 
the upper lobe bronchus (which is located closely posterior) 
or the anterior portion of the fissure.
On the right side the superior pulmonary vein can be 
involved because of tumors infiltrating the fissural portion 
of the PA, which is located tightly behind the vein.
Full control of the main bronchus can be achieved 
without significant problems if a sleeve resection is 
technically feasible. The core of bronchial and/or PA 
resection is the dissection in the interlobar fissure. The 
interlobar fissure is generally approached once complete 
control of the proximal PA has been achieved. Dissection in 
this site can be safer after proximal clamping of the artery. 
Technical expertise and mature surgical judgment are 
needed, because it is generally in this step of the operation 
that the tumor can be judged amenable to a sleeve resection 
or a PN, or considered unresectable. Shrinkage of tumor 
and fibrosclerotic reaction produced as a consequence 
of induction therapy usually increase the technical 
complexity of surgical dissection and may pose doubt in the 
identification of viable tumor at this site. Frozen-section 
histology should therefore be performed on all suspicious 
tissue. However, after chemotherapy or chemoradiotherapy, 
sleeve resection with reconstructive procedures may also be 
indicated when indissociable fibrotic tissue with no residual 
tumor is embedded in the bronchus and/or the PA. In some 
situations both the upper lobe bronchus and the PA can be 
encased in fibrotic tissue even without tumor cells at frozen-
section analysis. Because lobectomy is technically impossible 
and PN is the alternative, we think that this is a good 
indication for a combined bronchovascular reconstruction.
During dissection in the fissural plane, exposure of the 
arterial branches to the superior segment and to the anterior-
basal segment of the lower lobe has to confirm that the 
vasculature to the lower lobe is free from tumor and can be 
spared.
On the right side, it is also essential to verify the integrity 
of the arterial branch to the middle lobe, otherwise the 
middle lobe should be included in the resection.
We prefer to approach the fissure on the left side starting 
from its posterosuperior end, at the level of the main PA, 
proceeding with the dissection anteriorly and inferiorly in a 
subadventitial plane.
On the right side we expose the intrafissural artery 
behind the middle lobe and to identify the branch for the 
superior segment of the lower lobe by dissecting from 
front to back. To avoid extensive parenchymal dissection 
in the fissure the exposure can be continued posteriorly at 
the bifurcation between the upper lobe bronchus and the 
bronchus intermedius. A crotch lymph node is a frequent 
finding in this location. If cleavable, this lymph node can 
be elevated away from the bifurcation, allowing exposure of 
the PA branch to the superior segment of the lower lobe. 
Once this branch is identified, the posterior portion of the 
fissure can be completed with a linear stapler. The bronchus 
intermedius is encircled just distal to the upper lobe take-off 
and an umbilical tape is placed to aid the airway division at 
the appropriate site.
Resection and reconstruction 
The resection phase begins once the main and distal PA, 
the bronchus, and both pulmonary veins have been duly 
prepared. Before starting the dissection it is useful to clamp 
the previously prepared main PA. Clamping of the proximal 
PA is performed after systemic heparinization. In the past we 
used to clamp the inferior pulmonary vein to obtain backflow 
control when a sleeve resection of the artery was required. 
We now prefer to clamp the PA distally to the tumor 
infiltration. The dose of intravenous heparin represents the 
only intraoperative management modification adopted by the 
authors over time. We prefer to administer 1,500 to 2,000 
units (about 20–25 units/kg) instead of the dose between 
3,000 and 5,000 units that was used in the past. Heparin dose 
has been reduced to prevent postoperative oozing, especially 
from the lymphadenectomy sites, and has proved effective in 
avoiding the risk of thrombosis. Heparin is not reversed by 
protamin after declamping once the vascular reconstruction 
has been completed.
Technical aspects of reconstruction of the PA and 
the bronchus have been addressed in detail in previous 
publications (9-11) by the current authors and are briefly 
reported in this article.
Bronchial resection and reconstruction
After complete preparation of the bronchial structures, 
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the mainstem bronchus is divided just proximal to the 
upper lobe take-off. Once the bronchus has been sectioned 
proximally (Figure 2), the definitive decision to proceed 
with a sleeve resection is made based on macroscopic and 
microscopic findings. The bronchus is divided distally at 
the inferior upper lobe take-off. Bronchial cuts must be 
perpendicular to the long axis of the airway. Microscopic 
tumor found at a bronchial margin requires additional 
resection of the involved areas or possibly PN.
Even though different techniques have been described 
for bronchial anastomotic reconstruction, the current 
authors’ preference is for the use of interrupted sutures of 
4/0 monofilament adsorbable material (11). Sutures are 
placed circumferentially starting from the junction between 
the cartilaginous and the membranous parts of the bronchus 
on the mediastinal side and proceeding toward the lateral 
side. Sutures are subsequently tied after their placement has 
been completed. By accurately calibrating distances between 
sutures it is possible to compensate for even large-caliber 
discrepancies between the two bronchial stumps.
This technique prevents torsion of the bronchial axis and 
gently stretches the circumference of the distal bronchus. 
The standardized use of continuous running sutures 
(complete or partial) has also been reported by other 
investigators (12,13).
Pulmonary artery reconstruction after sleeve resection
End-to-end anastomosis
In patients that require a combined bronchovascular 
sleeve with PA reconstruction is usually performed after 
completion of the bronchial anastomosis to minimize the 
manipulation of the vessel. 
When transecting the artery, both proximally and 
distally, regular and even margins are desirable, even at the 
cost of some loss of tissue. This allows proper placement 
of the stitches and yields an even inside lumen. In addition, 
regular suture borders facilitate the correction of the large 
caliber discrepancy that usually occurs. In addition, the 
exposure of the bronchial stumps is optimal when the 
artery is divided. If the vascular and bronchial procedures 
are done simultaneously, the bronchial axis is shortened, 
and the PA stumps are opposable with acceptable tension. 
On completion of the bronchial anastomosis, the distance 
between the two arterial ends will be markedly decreased, 
and it can be further reduced by elevating the lower lobe 
while suturing. Restoration of blood flow and removal of 
the proximal clamp relieves any residual tension. If the 
distance between the arterial stumps is deemed excessive, 
the interposition of a prosthetic conduit is indicated. 
The anastomosis is performed with running 5-0 or 6-0 
monofilament non-absorbable material. Additionally, 
the sutures are placed very carefully to avoid stenosis. 
End-to-end anastomosis can be technically difficult due 
to unexpected traction between the stumps and caliber 
discrepancy (Figure 3).
Long-segment PA reconstruction
In some patients after sleeve resection of the PA an 
excessive distance between the two vascular stumps may 
result. This condition could produce a high tension on the 
anastomosis. Such technical situation may occur, usually 
on the left side, in those cases requiring resection of a long 
segment of the PA without associated bronchial sleeve 
resection, because the lobar bronchus is not involved. In 
these cases the vascular reconstruction cannot be performed 
Figure 3 Intraoperative view illustrating completed right bronchial 
and pulmonary artery reconstruction.
Figure 2 Intraoperative picture of double left upper sleeve lobectomy. 
Dissection and resection phases are completed.
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by a direct end-to-end anastomosis and a prosthetic conduit 
interposition is required.
Although the need for a vascular conduit is not a frequent 
condition, various materials and different techniques have 
been proposed for such reconstructive procedure. 
Biological materials are generally preferred because of 
higher biocompatibility and lower risk of thrombosis. The 
authors have reported the successful use of the autologous 
and the bovine pericardium (14). More recently, the current 
authors have introduced the use of porcine pericardium. 
Intraoperatively, the pericardial leaflet is trimmed to a 
rectangular shape and wrapped around a chest tube or a 
syringe of appropriate diameter and sutured longitudinally. 
In our initial experience this suture was performed 
manually with a 6-0 monofilament non-absorbable material. 
More recently we have described a technical alternative 
with a mechanical suture using a linear stapler for the 
conduit construction. The creation of a 1–2 cm conduit 
is so accomplished. When the autologous pericardium 
is employed the epicardial surface is oriented inside the 
conduit lumen. 
A very interesting alternative for conduit reconstruction 
is represented by the superior pulmonary vein of the 
resected upper lobe when the extra-parenchymal portion of 
this vessel is free from tumor (15,16). The technique used in 
order to obtain the PV conduit has been described in detail 
in previous publications (15) (Figure 4). 
The venous conduit is an ideal substitute for PA 
replacement since it has adequate thickness and structural 
similarity with the arterial wall. It is advisable to tailor the 
length of the biological conduit on the basis of the resected 
arterial segment, because the elasticity of the two tissues is 
comparable. 
The proximal anastomosis is performed first with 
running 5-0 monofilament suture. The distal anastomosis is 
then performed with the same technique, after the conduit 
length has been checked.
Care must be taken to avoid lengthening of the 
reconstructed PA, which may cause kinking of the vessel, 
impaired blood flow and therefore thrombus formation.
For the final success of the reconstruction, it is 
fundamental to avoid tension on the anastomosis. Tension 
release can be improved by sectioning the inferior 
pulmonary ligament and, on the right side, by opening the 
pericardium around the inferior pulmonary vein.
Viable tissue flap for prevention of bronchoarterial fistula
Bronchoarterial fistula can be effectively prevented 
by interposing a viable tissue flap between the two 
structures. The use of mediastinal fat pad, pericardial flap, 
or pleural flap has been reported (12,17). However, an 
intercostal muscle flap is preferable because of its excellent 
vascularization provided by the intercostal artery (18).
The preparation of the flap is performed before opening 
the chest, and the rib retractor is not inserted until the 
procedure is completed to avoid crushing the intercostal 
vessels. The periosteum of the fifth rib is incised and then 
separated from the bone in continuity with the underlying 
intercostal muscle. Care must be taken to preserve the 
muscular insertion to the periosteum to avoid injuring the 
intercostal neurovascular bundle. The intercostal muscle is 
then incised in the vicinity of the underlying sixth rib and 
the anterior insertion of the flap is divided. The pedicle 
Figure 4 Pulmonary artery conduit reconstruction on the left side. After vascular sleeve resection the PA is reconstructed by autologous pulmonary 
vein conduit. (A) Distal anastomosis with 5-0 non-absorbable running suture; proximal anastomosis is completed; (B) anastomotic suture has been 
completed but still untied. PA, pulmonary artery.
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is ligated at its anterior extremity. When the bronchial 
anastomosis is completed, a large right-angle clamp is slid 
between the pulmonary artery and the bronchus, and the 
suture at the extremity of the flap is slid backward around 
the bronchial anastomosis and between the bronchus and 
the pulmonary artery. The flap is then twisted until its 
pleural side is in contact with the bronchial anastomosis 
and the pleura are secured to the bronchus by interrupted 
absorbable 4-0 sutures.
Comment
Bronchovascular reconstructive procedures have provided 
excellent oncological results, similar or even better 
than those obtained by PN (6-8,19-30) (Table 1). When 
considering more recent literature experiences, the analysis 
of long-term survival according to stage and nodal status 
shows that sleeve lobectomy results in higher survival 
rates for stages I and II. The survival advantage in stage 
III patients appears to be limited (6,8,23), and the role of 
parenchymal sparing operations in patients with N2 disease 
still remains undefined (21,31).
Nagayasu and colleagues (30) comparing long-term 
results of bronchovascular reconstructions performed in two 
different time periods along more than 30 years, reported 
results dramatically influenced by the high rate of pN2 
and even pN3 patients treated during the first period, thus 
indicating the importance of a correct surgical indication 
when performing reconstructive procedures for lung cancer.
It has been demonstrated (10,32) that the survival of 
patients undergoing PA reconstruction is comparable, 
stage-by-stage, to that reported in the major reviews on 
lung cancer surgery and bronchial sleeve resection in the 
literature. The impact of nodal status on survival is also 
comparable to that reported for bronchial sleeve and 
standard resection. Once the decision to resect the disease 
with intent to cure is taken, PA reconstruction can also 
be proposed as an adequate procedure in this setting. 
Moreover, there is no significant difference between PA 
reconstruction alone and PA reconstruction associated with 
bronchial sleeve in terms of postoperative mortality and 
morbidity (33). A new interesting information that surfaces 
from our more recent study (10) and is different from our 
previous report (32) is that combined bronchovascular 
reconstructions may offer better survival. This suggests that 
even this complex lung-sparing operations can be pursued 
with intent to cure as long as a complete anatomic resection 
is achieved (10,23,32-36).
However, postoperative morbidity and mortality data 
reveal overall better results for patients undergoing SL with 
respect to PN (8,19,20,26) (Table 2). 
An interesting meta-analysis (37) including series 
published between 1996 and 2006 has compared early and 
long-term outcome of SL with those of PN. A total of 2984 
patients have been included in this analysis, of which 21% 
undergoing SL and 79% undergoing PN. Two-hundred-
two patients underwent PA resection and reconstruction 
in association (164 patients) or not (38 patients) with a 
bronchial sleeve resection. 
Morbidity evaluation from eight studies (7,19-22,24,38,39) 
Table 1 Long-term oncological results of main series comparing SL with PN published in the last 10 years
Author [year]
Patients L-recurrence (%) D-recurrence (%)  5-year survival (%)
SL PN SL PN SL PN SL PN
Bagan [2005] (22) 66 151 4.5 7.6 – – 72.5 51.2
Kim [2005] (7) 49 49 22.0 6.0 22.0 20.0 53.7 59.5
Lausberg [2005] (23) 171 63 36.2 21.3 – – 45.0 30.4
Ludwig [2005] (21) 116 194 – – – – 39.0 27.0
Takeda [2006] (24) 62 110 9.7 10.9 29.0 49.7 54.1 39.2
Parissis [2009] (8) 79 129 17.7 19.4 – – 46.8 37.1
Park [2010] (26) 105 105 14.3 16.2 11.4 21.9 58.4 32.1
Gómez-Caro [2011] (27) 55 21 3.6 33.0 38.0 71.0 61.0 31.0
Maurizi [2013] (28) 39# 39# 5.1 2.6 15.4 28.2 64.0 34.5
Andersson [2015] (29) 40 67 2.5 4.5 32.5 32.8 37.5 41.8
 #, all post-neoadjuvant therapy patients. L-recurrence, local recurrence; D-recurrence, distant recurrence; SL, sleeve lobectomy; PN, 
pneumonectomy.
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showed a pooled incidence of 31.3% in the SL group and 
of 31.6% in the PN group without statistically significant 
difference. Similar results were observed limiting the 
analysis to studies reporting a larger experience (more than 
50 patients) of SL. The mean postoperative complication 
rate reported after PA reconstruction was similar (32.4%) 
to that reported after bronchial SL and PN. Overall 
postoperative mortality presented a pooled incidence 
of 3.5% in the SL group and of 5.7% in the PN group, 
but this difference did not reach statistical significance. 
However, when considering only studies with larger number 
(over 50) of SL, mortality rate was significantly lower in the 
SL group than in the PN group (6,19-24,40). 
Literature data show that PN patients appear to 
experience a higher rate of cardiac complications 
when morbidity is evaluated according to the type of 
complication, while SL patients show increased pulmonary 
and airway complications incidence (7,19-21,31).
Overall 5-year survival rate from 10 studies (6,7, 
20-24,36,38,39) was 50.3% after SL and 30.6% after PN, 
showing a statistically significant difference. 
The pooled loco-regional recurrence rate from studies 
considered in this meta-analysis resulted 16.1% in the SL 
group and 27.8% in the PN group, but this difference did 
not reach statistical significance. Otherwise, a significantly 
lower incidence of local recurrence in favour of SL (SL, 
14.5% vs. PN, 28.7%) was reported in the studies with 
larger number of sleeve procedures (6,20,22,24). 
The preservation of lung parenchyma has been indicated 
by some authors as the possible cause of a theoretical 
increased risk for loco-regional recurrence after SL. 
However although in some experiences (31) a higher 
local recurrence rate is reported for sleeve resection with 
advanced nodal status (N2), the few studies (7,31) analyzing 
risk factors for recurrence, show that the tumor stage and 
the nodal status are the only negative predictive factors, 
rather than the type of operation performed.
When considering patients with locally advanced 
non-small cell lung cancer, induction chemotherapy or 
chemoradiotherapy has become a standardized indication 
especially in the presence of N2 disease. However, although 
the beneficial prognostic effects of neoadjuvant therapy 
have been proved, concern about an increased risk of 
complications when complex reconstructive procedures 
are performed after oncologic treatment, has limited the 
diffusion of such operations within multimodality treatment 
options. Additional risks may be related to the increased 
difficulty in surgical dissection caused by diffuse fibrotic 
reaction, and to the potential healing impairment of the 
reconstructed bronchus caused by tissue damage and 
compromised vascularization.
After induction treatment, the dissection of the 
pulmonary hilum and mediastinum can be difficult and 
hazardous because the bronchial and vascular structures 
may be embedded in the desmoplastic reaction and scarring 
tissue produced by the chemotherapy and radiotherapy. 
Technical expertise and mature surgical judgment are 
needed, because it is generally in this step of the operation 
that the tumor can be judged amenable to a sleeve resection 
or a PN, or considered unresectable. Shrinkage of tumor 
and fibrosclerotic reaction produced as a consequence 
of induction therapy usually increase the technical 
Table 2 Morbidity and mortality from the main recent series comparing SL with PN
Author [year]
Patients Complications (%) Mortality (%)
SL PN SL PN SL PN
Bagan [2005] (22) 66 151 28.8 29.9 4.5 12.6
Kim [2005] (7) 49 49 7.4 44.0 6.1 4.1
Lausberg [2005] (23) 171 63 0.6* 7.9* 1.7 6.3
Ludwig [2005] (21) 116 194 38.0 26.0 4.3 4.6
Takeda [2006] (24) 62 110 45.0 40.9 4.8 3.6
Parissis [2009] (8) 79 129 16.4 21.6 2.5 8.5
Park [2010] (26) 105 105 29.5 33.4 1.0 8.6
Gómez-Caro [2011] (27) 55 21 32.0 33.0 3.6 5.0
Maurizi [2013] (28) 39# 39# 28.2 33.3 0 2.6
Andersson [2015] (29) 40 67 50.0 44.8 2.5 6
*, bronchial complications; #, all post-neoadjuvant therapy patients. SL, sleeve lobectomy; PN, pneumonectomy.
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complexity of surgical dissection and may pose doubt in the 
identification of viable tumor at this site. Frozen-section 
histology should therefore be performed on all suspicious 
tissue. However, after chemotherapy or chemoradiotherapy, 
sleeve resection with reconstructive procedures may also be 
indicated when indissociable fibrotic tissue with no residual 
tumor is embedded in the bronchus and/or the PA. In some 
situations both the upper lobe bronchus and the PA can be 
encased in fibrotic tissue even without tumor cells at frozen-
section analysis. Because lobectomy is technically impossible 
and PN is the alternative, we think that this is a good 
indication for a combined bronchovascular reconstruction. 
In their initial experience the current authors first reported 
in 1997 the possibility of performing bronchial and arterial 
sleeve resection after induction chemotherapy with no 
mortality, no bronchial and vascular complications, and no 
local recurrence in the airway. The overall perioperative 
morbidity rate in a series of 27 patients was similar to that 
reported in patients undergoing postinduction standard 
resection in the same period. In addition, 1- and 4-year 
survival rates (78% and 39%) did not show significant 
differences from those reported in the standard resection 
series (65% and 36%) (41,42). These results have 
subsequently been reproduced and further developed by 
other investigators worldwide, but available data remain 
limited, with the largest published series including fewer 
than 50 patients (43).
In 2013 the authors published the long-term results of 
their experience comparing SL with PN after induction 
chemotherapy (28). A total of 39 patients undergoing 
bronchial and/or vascular reconstruction associated with 
lobectomy were analyzed and compared with 39 patients 
undergoing PN over a 14-year period. Postoperative 
complications occurred in 28.2% of patients receiving 
bronchovascular reconstruction and in 33.3% of the PN 
group, without statistically significant difference between 
the two surgical options. Complications related to the 
reconstructive procedure occurred in one patient: a late 
stenosis of the bronchial anastomosis was observed and it 
was successfully treated by laser and stenting. Postoperative 
mortality rate in the PN group was 2.6%, while there was 
no mortality in the SL group. Difference in postoperative 
mortality was not significant (P=0.3). 
The tumor recurrence rate was 20.5% in the SL group 
(loco-regional in 2 patients, distant in 6) and 30.8% in the 
PN group (loco-regional in 1 patient, distant in 11), but this 
difference was not significant. In particular there was no 
significant difference between the two groups if considering 
loco-regional recurrence rate only.
Literature data also indicate that lung parenchyma 
sparing improves postoperative quality of life determining 
a greater cardio-pulmonary reserve, less pulmonary edema 
and less right ventricular dysfunction due to a lower 
pulmonary vascular resistance. In an interesting paper from 
Ferguson the Quality Adjusted Years Quoted was 4.37 after 
SL and 2.48 after PN (44). Another paper from Melloul 
has retrospectively analysed postoperative FEV1 reporting 
significantly higher values for patients undergoing SL (25). 
In a prospective study from Martin-Ucar the reported 
mean FEV1 loss after parenchymal sparing operations 
was considerably less than after PN, indicating a strongly 
significant prognostic advantage for patients undergoing 
SL. Similarly, a recent propensity-matched analysis from 
Andersson and colleagues (29) compared the outcome after 
SL with that after PN reported postoperative quality of 
life results for moving and breathing favouring SL with 
respect of PN; thus demonstrating the functional benefit 
after lung sparing reconstructive procedures. If considering 
SL in comparison with standard upper lobectomy instead 
of PN, a recent study from the current authors has shown 
no significant difference in term of functional outcome and 
quality of life (45). These last evidence enforces the role 
of SL as an available choice for the treatment of centrally 
located lung cancers.
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